Vaxart (VXRT) Misses Q2 EPS by 3c

Vaxart (NASDAQ: VXRT) reported Q2 EPS of ($0.06), $0.03 worse than the analyst estimate of ($0.03). Revenue for the quarter came in at $27.19 million versus the consensus estimate of $50.5 million.

For earnings history and earnings-related data on Vaxart (VXRT) click here.

You May Also Be Interested In

• Bessent: We Make A Market Buying Older Bonds
• Ramp In Talks For New Funding At $60 Billion Valuation - Bloomberg
• B.Riley on Viking Therapeutic (VKTX): 'we continue to see an attractive setup'